L, a lead ULSC program, following the recent Orphan Drug Designation • Recently reported Phase 1 data of Restem-L demonstrated a clinically meaningful efficacy and significant reduction in steroid use ...

New research from Tokyo, Japan could help clarify the role of proinflammatory mediators in the pathogenesis of chronic inflammatory myopathies, such as polymyositis and dermatomyositis.

Medically reviewed by Dale Garber, MD Juvenile myositis (JM) affects those under the age of 18 years. JM is known for causing ...

YTS-109 is under clinical development by Bristar Immunotech Biotechnology and currently in Phase I for Polymyositis.

ULSCs is under clinical development by RESTEM and currently in Phase I for Dermatomyositis. According to GlobalData, Phase I drugs for Dermatomyositis have a 91% phase transition success rate (PTSR) ...

Myopathic (myo = muscle, pathy = disease) conditions can include polymyositis, dermatomyositis, inclusion body myositis, and various myopathies due to metabolic, congenital, and endocrine causes.

Polymyositis is an autoimmune disease that causes inflammation and weakness of the skeletal muscles responsible for movement. Dermatomyositis is a form of polymyositis that is associated with skin ...

CORONA, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune ...

There are different types of Myositis — Polymyositis and Dermatomyositis are the most common ones. Popular actress Samantha Prabhu, last week, announced on Instagram that she was suffering from ...

- Oral presentation at ACR highlights safety and efficacy data from the Phase 1 trial of umbilical cord outer lining-derived stem cells (ULSCs) in patients with ...